NAVEEN MISHRA: Open Payments
NPI 1336247733 · ROSEVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$847 in 34 payments from 9 companies in 2025. Trend: 2023 $620 · 2024 $806 · 2025 $847
Food & beverage: $735Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $185 |
| E.R. Squibb & Sons, L.L.C. | 5 | $150 |
| Janssen Pharmaceuticals, Inc | 5 | $123 |
| ABBVIE INC. | 6 | $116 |
| Alkermes, Inc. | 4 | $98 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Neurocrine BioSciences, Inc. | 2 | $40 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
Products named: COBENFY, INVEGA SUSTENNA, VRAYLAR, ARISTADA, CAPLYTA, REXULTI, AUSTEDO XR, INGREZZA.
Industry payments across CA — which companies pay providers there.
